Cibisatamab is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cibisatamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cibisatamab (RG-7802) is under development for the treatment of advanced metastatic CEA-positive solid tumors including metastatic colorectal cancer, squamous non-small cell lung cancer (first and third line therapy), breast cancer, pancreatic cancer, gastric cancer including gastroesophageal junction cancer. The drug candidate is administered through intravenous route. This antibody acts as a bi-specific T-cell engager. The drug candidate acts by targeting carcinoembryonic antigen (CEA, CEACAM5, and CD66e) antigen on tumor cells and CD3 on T cells. It is a new molecular entity (NME).
F. Hoffmann-La Roche overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
For a complete picture of Cibisatamab’s drug-specific PTSR and LoA scores, buy the report here.